Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion
https://doi.org/10.4081/dr.2023.9803
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Scleromyxedema (SMX), the generalized and sclerodermic form of lichen myxedematous (LM), is a chronic mucinosis characterized by cutaneous manifestation and several systemic comorbidities. Treatment options are limited and there are no definitive therapeutic guidelines. We report a case of a 48-year-old man with scleromyxedema, associated with monoclonal gammopathy and arthritis, who has been successfully treated with intravenous immunoglobulins (IVIg), oral corticosteroids, and methotrexate (MTX). IVIg is the most used first-line therapy for SMX based on its efficacy and well-tolerated nature and has been used for a growing number of skin disorders. In our case, combining IVIg with oral prednisone and MTX allowed better control of skin disease and extra-cutaneous manifestations. To the best of our knowledge, this is the first case of a successful treatment for SMX with a combination of therapeutic strategies and a good safety profile.
Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg. 2006;25(2):100-104. doi:10.1016/j.sder.2006.04.001 DOI: https://doi.org/10.1016/j.sder.2006.04.001
Caudill L, Howell E. Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin. J Clin Aesthet Dermatol. 2014;7(5):45-47.
Edward M, Fitzgerald L, Thind C, Leman J, Burden AD. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br J Dermatol. 2007;156(3):473-479. doi:10.1111/j.1365-2133.2006.07652.x DOI: https://doi.org/10.1111/j.1365-2133.2006.07652.x
Cárdenas-Gonzalez RE, Ruelas MEH, Candiani JO. Lichen myxedematosus: a rare group of cutaneous mucinosis. An Bras Dermatol. 2019;94(4):462-469. Published 2019 Oct 17. doi:10.1590/abd1806-4841.20198478 DOI: https://doi.org/10.1590/abd1806-4841.20198478
Kreuter A, Stücker M, Kolios AG, Altmeyer P, Möllenhoff K. Skleromyxödem. Eine chronisch progressive Systemerkrankung [Scleromyxedema. A chronic progressive systemic disease]. Z Rheumatol. 2012;71(6):504-514. doi:10.1007/s00393-012-0997-5 DOI: https://doi.org/10.1007/s00393-012-0997-5
Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69(1):66-72. doi:10.1016/j.jaad.2013.01.007 DOI: https://doi.org/10.1016/j.jaad.2013.01.007
Sáez-Rodríguez M, García-Bustínduy M, López-Alba A, et al. Localized lichen myxoedematosus (papular mucinosis) associated with morbid obesity: report of two cases. Br J Dermatol. 2003;148(1):165-168. doi:10.1046/j.1365-2133.2003.05117.x DOI: https://doi.org/10.1046/j.1365-2133.2003.05117.x
Rongioletti F, Parodi A, Rebora A. Papular and nodular mucinosis as a sign of lupus erythematosus. Dermatologica. 1990;180(4):221-223. doi:10.1159/000248034 DOI: https://doi.org/10.1159/000248034
Wong RX, Chia JC, Haber RM. Review of Primary Cutaneous Mucinoses in Nonlupus Connective Tissue Diseases. J Cutan Med Surg. 2018;22(1):65-70. doi:10.1177/1203475417719053 DOI: https://doi.org/10.1177/1203475417719053
Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol. 2001;23(3):257-267. doi:10.1097/00000372-200106000-00022 DOI: https://doi.org/10.1097/00000372-200106000-00022
Knobler R, Moinzadeh P, Hunzelmann N, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol. 2017;31(10):1581-1594. doi:10.1111/jdv.14466 DOI: https://doi.org/10.1111/jdv.14466
Majeski C, Taher M, Grewal P, Dytoc M, Lauzon G. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg. 2005;9(3):99-104. doi:10.1007/s10227-005-0137-9 DOI: https://doi.org/10.1007/s10227-005-0137-9
Kim S, Park TH, Lee SM, et al. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin. Dermatol Ther. 2020;33(3):e13378. doi:10.1111/dth.13378 DOI: https://doi.org/10.1111/dth.13378
Bidier M, Zschoche C, Gholam P, Enk AH, Hadaschik EN. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol. 2012;92(4):408-409. doi:10.2340/00015555-1299 DOI: https://doi.org/10.2340/00015555-1299
Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484-486. doi:10.1126/science.291.5503.484 DOI: https://doi.org/10.1126/science.291.5503.484
Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol. 2006;24(6):493-497. doi:10.1016/j.clindermatol.2006.07.011 DOI: https://doi.org/10.1016/j.clindermatol.2006.07.011
Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol. 2008;74(3):248-250. doi:10.4103/0378-6323.41372 DOI: https://doi.org/10.4103/0378-6323.41372
Xu XL, Wu Q, Zeng XS, Sun JF. Combination of betamethasone and methotrexate for the treatment of scleromyxoedema without paraproteinaemia. Eur J Dermatol. 2016;26(4):391-393. doi:10.1684/ejd.2016.2794 DOI: https://doi.org/10.1684/ejd.2016.2794
Mehta V, Balachandran C, Rao R. Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol. 2009;54(2):193-195. doi:10.4103/0019-5154.53183 DOI: https://doi.org/10.4103/0019-5154.53183
Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum. 2008;38(3):188-194. doi:10.1016/j.semarthrit.2007.10.015 DOI: https://doi.org/10.1016/j.semarthrit.2007.10.015
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
